GLP-1 / GIP / glucagon

Retatrutide

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

Retatrutide is listed in the ezGLP knowledgebase under GLP-1 / GIP / glucagon. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: GLP-1 / GIP / glucagon
Routes represented: Subcutaneous (SubQ)
Approximate library half-life: 144 hours; formulation-dependent and not dosing guidance
Storage context: Follow the dispensed product label; storage and in-use limits vary by brand and formulation.

Published literature

Safety evidence

Common or reported: nausea, diarrhea, vomiting, constipation.

Investigational; long-term and rare adverse effects are not established.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With Pramlintide

Safety flag

Additive gastric-emptying delay, GI intolerance, and glucose lowering are plausible; a broad clinical contraindication is not established.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.